📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Praticien-chercheur
8 articles scientifiques publiés — formation continue solide
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Lupus · 2008
Mycophenolate mofetil (MMF) with prednisolone has been associated with high remission rates when used as induction treatment for lupus nephritis. This prospective, multicentre, cohort study investigates the efficacy and safety of this regimen over 24 weeks in 213 Chinese patients with active lupus nephritis (Classes III, IV, V or combination). Baseline activity index (AI) was 6.91 ± 3.33 and chronicity index (CI) was 1.9 ± 1.2. The remission rate was 82.6% at 24 weeks (complete remission, 34.3%; partial remission, 48.4%). There were significant ( P < 0.01) improvements in kidney function shown by reductions in proteinuria, serum albumin, serum creatinine and creatinine clearance, as well as in systemic lupus erythematosus disease activity index (SLEDAI) scores. Independent risk factors influencing remission were pathological classification (including Class V and III or Class V and IV nephritis) and elevated serum creatinine at baseline (OR 2.967, 95% CI: 1.479–6.332, P = 0.001 and OR 1.007, 95% CI: 1.002–1.011, P = 0.001, respectively). Patients with concomitant membranous features on biopsy had a lower remission rate than those with Class III and IV nephritis (66.7% vs 87.3%, P = 0.002). Renal biopsy was repeated in 25 patients following treatment. There was a transition to less severe pathological morphologies in majority of subjects. Infections were monitored throughout treatment: eight patients (3.8%) experienced bacterial infections, whereas herpes zoster occurred in seven patients. Nine patients (4.2%) suffered from gastrointestinal upset, which resolved without discontinuation of MMF. One patient became leucopenic, whereas another died from active disease unrelated to kidney symptoms. MMF combined with prednisolone is an effective and well-tolerated induction treatment for patients with active lupus nephritis and for controlling SLE systemic activity.
Expert review of hematology · 2020
The Israel Medical Association journal : IMAJ · 2011
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
BMJ case reports · 2026 · Journal Article
F A, George OK, Alex AG, Sahitya MS
The Pan African medical journal · 2022 · Case Reports
Yacouba MN, Francine SB, Francois BNJ, Paul EO, et al.
Health psychology report · 2025 · Journal Article
AlBurno H, Francine S, de Vries H, Mohanadi DA, et al.
Expert review of hematology · 2020 · Journal Article
Jennifer C Z, Sara Mohamed J, Salma A, Francine F
Drug design, development and therapy · 2019 · Journal Article
Kameoka Y, F K, M K
The Israel Medical Association journal : IMAJ · 2011 · Journal Article
Plakht Y, Shiyovich A, Francine L, Shoshan Y, et al.
Lupus · 2008 · Clinical Trial
F L, Y T, X P, L W, et al.
Clinical case reports · 2026 · Journal Article
Evele G, Francine K, Bardin R
Health psychology report · 2025 · Journal Article
AlBurno H, Francine S, de Vries H, Mohanadi DA, et al.